



DCVMN 23rd Annual General Meeting

Speakers Book

Pune, India

20 - 22 October 2022



DCVMN

Developing Countries Vaccine
Manufacturers Network



20
OCT

14:00 - 15:30

Inaugural Session

LAMP LIGHTING



Honorable Minister Dr. Mansukh Mandaviya

Minister of Health and Family Welfare and Chemical and Fertilizers of India, GOI

Doctor of Philosophy degree (PhD), on the subject of 'Role of Gram Vidhyapiths (Rural Schools) in Community Development and Future Challenges', in the field of Political Science, from the Gujarat Institute of Development and Research, Ahmedabad, India. Known for organizing Gandhian Philosophy based long padayatra (foot marches) to spread awareness for girl child education (150 years of Gandhi) in the state of Gujarat. Currently, Member of the Rajya Sabha (Upper House of Indian Parliament), representing the state of Gujarat, India and Cabinet Minister, holding portfolio of Ministry of Health & Family Welfare and Chemicals & Fertilizers, in the union government prior to this also held Road Transport & Highways, Ports, Shipping & Waterways ministries as Minister of State. Executive Board Member for GAVI and Chairperson, Stop TB Board Partnership. Credited with setting up over 8000+ Jan Aushadi Kendras (Generic and Affordable Medicine Stores) and scaling up the country's vaccination drive to achieve a billion doses in the shortest period of time. Honoured by UNICEF for contributions to women's menstrual hygiene. In 2015, selected to represent India at the United Nations; spoke about the 2030 Agenda for Sustainable Development.

OPENING ADDRESS



Mr. Adar C. Poonawalla

CEO, Serum Institute of India

Mr. Adar has successfully led the expansion of the SII for over 170 countries, focusing on ensuring affordable, licensed and pre-qualified vaccines by WHO. New vaccines such as Rotavirus and Pneumococcal have been produced under his tenure since 2011. Even more, SII has produced 1.5 million doses of the COVID-19 vaccine and 1.5 billion of others distributed worldwide.

INITIATION OF CEREMONY



Mr. Rajinder Suri

CEO, DCVMN

To meet un-precedented challenge posed by COVID-19, Rajinder as CEO-DCVMN is actively involved in all global strategic initiatives along with COVAX partners and industry associations to ensure equity and timely access to vaccines. He is member of several advisory expert groups including COVAX Manufacturing & Supply Task Force Leadership Team and Market Design and Demand Intelligence pillar of PAVM. He brings over 25 years of top management experience in the industry including Board of Directors of the Indian subsidiary of Sanofi Pasteur and. Rajinder has been Member- GAVI-PPC of as well as Vice-President, DCVMN Executive Committee.

WELCOME TO THE SESSION



Mr. Sai D. Prasad

Board Chair, DCVMN - Executive Director, Bharat

Sai Prasad is the Executive Director at Bharat Biotech. He is responsible for crucial decisions in the company with respect to operations, business development and International Collaborations. He has expertise in areas not restricted to product development, contract negotiations, technology licensing, mergers & acquisitions, fund raising, overall operations, etc.



Dr. Tedros A. Ghebreyesus

Director General, WHO

A globally recognized health scholar, researcher, and diplomat, Dr. Tedros has been acting as WHO Director General since 2017 and was re-elected in 2022 for a second 5 year-term. Immediately after taking office, Dr. Tedros outlined five key priorities for the Organization: Universal Health Coverage; Health Emergencies; Women's, Children's and Adolescents' Health; Health impacts of climate and environmental change; and transformed WHO.



Dr. Ayoade Alakija

Special Envoy & Co-chair for the ACT–Accelerator, WHO

Dr Alakija is a Pan-African visionary, innovative leader and influencer in global health and humanitarian development. In addition to her successful leadership role at WHO, she is also the Chair of the African Union, African Vaccine Delivery Alliance and Founder of the Emergency Coordination Centre, Nigeria (ECC), as well as the former Chief Humanitarian Coordinator for Nigeria.



Dr. Seth Berkley

CEO, GAVI

Medical doctor and infectious disease epidemiologist Dr Seth Berkley joined Gavi, the Vaccine Alliance as CEO in 2011. In 2020, he co-created COVAX, the only multilateral solution aimed at ensuring equitable access to COVID-19 vaccines for people in all countries. Previously, Dr Berkley was President and CEO of the International AIDS Vaccine Initiative (IAVI).



Dr. Richard Hatchett

CEO, CEPI

Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations, or CEPI – a global partnership that supports the swift development of and equitable access to new vaccines and other defenses against infectious diseases with epidemic and pandemic potential. Dr Hatchett's and CEPI's plan is for the world to neutralize those pandemic threats with prescient investment in scientific R&D.



Dr. Bruce Aylward

Special Advisor to DG, WHO

Dr. Aylward is a Canadian physician and epidemiologist who leads the multi-agency Access to COVID-19 Tools Accelerator (ACT-A) Hub, an international collaboration to fast-track the development and equitable global distribution of new COVID-19 diagnostics, therapeutics and vaccines. Since the 1990s, Dr Aylward has worked for WHO in a variety of increasing leadership positions in the areas of emergencies, disease eradication and vaccines.



Dr. Soumya Swaminathan

Chief Scientist, WHO

Dr. Soumya Swaminathan is a paediatrician and a globally recognized researcher on tuberculosis and HIV with more than 450 renowned peer-reviewed publications. Before joining WHO for ensuring timely and advanced of health technology in 2019, she was Secretary to the Government of India for Health Research and Director General of the Indian Council of Medical Research from 2015 to 2017.



Dr. Carissa F. Etienne

Director, PAHO

Dr. Etienne, a native of Dominica, was elected for a second five-year term as the Director of the Pan American Health Organization, Regional Office of the World Health Organization in 2017. Dr. Etienne served as Assistant Director-General for Health Systems and Services at the World Health Organization in Geneva, Switzerland from 2008 to 2012.

**Mr. Nikolaj Gilbert**

President & CEO, PATH

Nikolaj Gilbert is president and chief executive officer of PATH. He brings more than 20 years of international experience as a leader, strategist, and director of complex partnerships. With a proven track record in both the private and public sectors, his expertise spans health, peacebuilding, humanitarian aid, and development solutions.

20
OCT

16:00 - 17:30

Pandemic Preparedness Response

CHAIR

**Prof. Helen Rees**

Founder & Chairperson, WITS RHI

Professor Helen Rees is the Executive Director of Wits RHI, the largest research Institute at Wits University in South Africa. Rees is an award-winning global health researcher whose research focusses on vaccine-preventable diseases, HIV and sexual and reproductive health. She is Board Chair of the South African Health Products Regulatory Authority and holds multiple leading positions in global health institutions.

**Dr. Kerim Chitour**

Global Head of Clinical, Center for Vaccine Innovation, and Access, PATH

Kerim Chitour, MD, is the Global Head of Clinical for PATH's Center for Vaccine Innovation and Access (CVIA), where he provides scientific and technical leadership for clinical development and pharmacovigilance activities across the PATH CVIA portfolio. Before joining PATH in 2021, Kerim worked at Takeda Pharmaceuticals' Vaccines Business Unit where, among other leadership roles, he was the Global Program Leader for the company's Sabin inactivated poliovirus vaccine.

**Mr. Thomas B. Cueni**

Director General, IFPMA

Cueni is the Director General of IFPMA, the global association of pharmaceutical research companies. He represents the innovative biopharmaceutical industry on the ACT-Accelerator. In addition, he is the Chair of the Business at OECD Health Committee and Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Cueni has been instrumental in creating the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance.

**Ms. Phyllis Arthur**

Science Policy, Biotechnology Innovation Organization

Phyllis Arthur, MBA in Business, collaborates with member companies in vaccines, antimicrobial resistance, molecular diagnostics and biodefense on policy, legislative and regulatory issues since 2009. Over her 16-year career in Marketing & Sales at Merck, she launched several vaccines with support from clinical and academic leaders, including the first HPV vaccine. In addition, she conducted several pieces of research at Brookings Institution, USA.

**Dr. Robin Moudy**

HHS OGA Pandemics & Emerging Threats, U.S.
Department of Health and Human Services

Dr. Robin Moudy is the Senior Advisor and Team Lead for Emerging Infectious Diseases and Response Policy within the U.S. Department of Health and Human Services Office of Global Affairs, where she leads pandemic and emerging infectious disease preparedness and response policy development and coordination.

**Dr. Adam Hacker**

Director Regulatory Affairs, CEPI

Adam Hacker is the Head of Global Regulatory Affairs, Coalition of Epidemic Preparedness Innovations (CEPI). As part of his role at CEPI, Adam co-chairs the COVAX Regulatory Advisory Group, consisting of thirteen regulatory authorities, where regulatory issues related to COVID-19 vaccine development are discussed. He has more than 20 years of pharmaceutical industry experience in leadership roles extending from Regulatory Affairs to Quality and Medical Affairs, including 10 years at Janssen.



Mr. Farid Fezoua

Global Director Health and Education, International Finance Corporation/World Bank Group

Farid is responsible for setting IFC's global strategies in health and education, managing a combined portfolio of more than \$4 billion. Prior to joining IFC, Farid was President & CEO of General Electric Africa, leading GE's operations in Sub-Saharan Africa, including developing sustainable solutions to strengthening health systems.



Dr. Marie Mazur

Director, Ready2Respond

Marie Mazur, PharmD, with 25 years of vaccine industry experience, is the Director of Ready2Respond, a coalition focusing on low- and middle-income countries' readiness to pandemics. Besides her leadership position, she serves on the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI) and on the Board of Directors of various organizations.



Dr. Akira Homma

Senior Advisor, Bio-Manguinhos/Fiocruz

Graduated DVMN in 1967, D.Sci in 1972. At FIOCRUZ since 1968. Director of Bio-Manguinhos/Fiocruz in two terms (1976-89; 2000-2009), President, Vice-President Fiocruz (1989; 1998-2000). Regional Advisor for Biologics for Americas/PAHO (1991-97). Former President DCVMN, Council of Trustees IVI, Executive Board GAVI. Currently, Senior Scientific Adviser of Bio-Manguinhos, member Technical Committee NIP, Vice President of Biotechnology/ABIFINA. Published 70 papers related to immunobiological.

21
OCT

09:00 - 10:30

Africa Forum: 'Kick the Tyres' (Panel discussion)

CHAIR



Dr. Ayoade Alakija

Special Envoy & Co-chair for the ACT-Accelerator, WHO

Dr Alakija is a Pan-African visionary, innovative leader and influencer in global health and humanitarian development. In addition to her successful leadership role at WHO, she is also the Chair of the African Union, African Vaccine Delivery Alliance and Founder of the Emergency Coordination Centre, Nigeria (ECC), as well as the former Chief Humanitarian Coordinator for Nigeria.



Dr. Nicaise Ndembi

Chief Science Advisor, Africa Centre for Disease Control and Prevention

Dr. Ndembi is also Research Professor at Kanazawa Medical University, where he also graduated in Medicine. He leads the Africa CDC's Partnerships for African Vaccine Manufacturing (PAVM) and Vaccine Strategy in Africa. He is a Principal investigator on +150 publications and has received numerous research grants including US NIH. He is editor-in-chief of several research journals, he serves on various WHO and US CDC Advisory Groups.



Dr. Matthew Downham

Director Manufacturing & Supply Chain Networks, CEPI

Dr. Downham, PhD, is responsible for the teams delivering CEPI's vaccine manufacturing and supply chain strategy supporting the priority pathogen project portfolio and geo-diversification of capacity-capability with national, regional and global partners to improve epi-/pandemic response preparedness, particularly in LMICs. Dr. Downham works with cross-functional teams/leadership, global stakeholders, vaccine manufacturing-supply chain partners establishing vaccine manufacture in alignment with the CEPI 2.0 strategy.

**Dr. Simone Blayer**

Global Head, Chemistry, Manufacturing, Control and Nonclinical Toxicology, PATH

Dr. Blayer oversees all vaccine process development, manufacturing and nonclinical toxicology studies required to initiate first-in-human clinical trials. Prior to joining PATH in 2019, he had championed essential projects on chemistry manufacturing and vaccine optimizations. In addition, as a member of the Center for Vaccine Innovation and Access team, he brings 20+ years of industrial experience in vaccine development, technological transfer production, and business intelligence.

**Prof. Nico Vandaele**

Access-To-Medicines Research Centre, KU Leuven, Belgium

Nico Vandaele, full professor at KU Leuven, holds the Janssen Pharmaceutica Research Chair on Pandemic Preparedness and leads, together with Catherine Decouttere, the Access-to-Medicines Research Centre, dealing with health system design in vaccine manufacturing, immunization, Covid-19, HIV and neglected tropical diseases in a global, regional, national and local context, collaborating with organizations like PATH, CEPI, PAVM, ZEPAI, NGOs, among others.

**Dr. Morena Makhoana**

CEO, Biovac

Dr. Makhoana holds the role of CEO and member of the Board and Executive team in Biovac, where he has been committed to building vaccine manufacturing capacity in Southern Africa since 2010. During his tenure, Biovac secured three successful technology transfers with global pharmaceutical companies, allowing a great growth in its staff. He has a strong record of advisory positions in healthcare and non-healthcare companies.

**Dr. Amadou Alpha Sall**

CEO, Institut Pasteur de Dakar – Chairman, Pasteur Network

Dr. Sall, virologist, is the CEO of Institut Pasteur de Dakar in Senegal, Chairman of Pasteur Network and former chairman of the Global Outbreak Alert and Response Network and director of the WHO collaborating center for Arboviruses and viral haemorrhagic fever. He is acknowledged by his expertise in epidemics response and control more specifically for arboviruses and viral haemorrhagic fevers (Ebola, Zika, Yellow fever ...).

**Prof. Petro Terblanche**

Managing Director, Afrigen Biologics

Holding several qualifications, Prof. Petro has a successful track record in the strategic management of technology intensive organizations, playing a key part in the design and implementation of South Africa's biotechnology strategy. Acknowledged as one of the legends in science and academia, she holds the position of Managing Director of Afrigen Biologics (Pty) Ltd and also part time Professor at the North-West University.

21
OCT

10:30 - 11:30

Sustainability and Lessons Learnt

CHAIR

**Ms. Julia Kuhn**

Associate Program Officer, BMGF

Julia Kuhn is an Officer on the Vaccine Development Team at the Bill & Melinda Gates Foundation. She supports CMC strategies, oversees portfolios for vaccine manufacturing workforce development and technologies to reduce animal testing among others. She received her Bachelor's degree from the University of Washington in Business Administration.

**Dr. Martin Nicholson**

Vaccine Manufacturing Expert Consultant, WHO

Martin is a vaccine manufacturing expert with WHO and works on sustainability and related activities within the mRNA technology transfer hub programme. He has over 10 years' experience in local production (LP) and previously led UNIDO's vaccine manufacturing support activities within its global LP project. He has also worked within the biotech and pharmaceutical industry, as well as biotech-focused venture capital and investment banking.

**Dr. Claudia Nannei**

Senior Technical Officer, WHO

Claudia Nannei is a health economist, specialized in management of health programmes, with more than 12 years' experience in university hospitals as strategic planning and performance monitoring expert and 12 years in WHO managing programmes on sustainable local production of vaccine in LMICs for pandemic preparedness and response. She is currently managing the WHO mRNA technology transfer hub initiative.

**Dr. Chris Chadwick**

Technical Officer for Influenza Preparedness and Response, WHO

Christopher Chadwick is a Technical Officer for Influenza Preparedness and Response at the World Health Organization, where he works on a range of policy issues, including R&D for influenza vaccines and other products, sustainable manufacturing, and virus sharing. He has an MS in public health microbiology and emerging infectious diseases and a BS in microbiology and chemistry.

**Ms. Frauke Uekermann**

Associate Director of Vaccine Markets, Clinton Health Access Initiative (CHAI)

Building on 20 years professional experience across the private, public and social sectors, she leads CHAI's market-shaping work for vaccines. Frauke collaborates closely with global stakeholders and supports DCVMs to improve vaccine access in LMICs. She holds a degree in Psychology from the University of Mannheim, Germany, and a PhD in Behavioural Economics from the University of St. Gallen, Switzerland.

**Dr. Heba Wali**

Chairman, VacSera Egypt

Dr. Heba is the President of the largest Holding Company for Biopharmaceuticals the only producer of vaccines in Egypt, besides being the oldest manufacturer in Africa and The Middle East. She led the production of the first million doses of COVID-19 vaccines in the country. In addition, she envisions to provide eight major vaccines globally through tech-transfer and secure.

**Dr. Stavros Nicolaou**

Group Senior Executive Strategic Trade, Aspen Pharma

Nicolaou has a consolidated experience in the South African and International Pharmaceutical Industry over 31 years. Being instrumental in introducing the first generic ARV's on the African Continent developed by Aspen, he has been appointed to several strategic advisory and lecturing designations nationally and globally. Holding several awards and recognitions, he is strongly committed to improve the access to treatment for patients in emerging markets, especially in South Africa.

**Mr. Patrick Tippoo**

Head of Science and Innovation, Biovac – Board, DCVMN

Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and present Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and currently serves as the Vice-President of DCVMN Mr. Tippoo is also member of the DCVMN's board.

21
OCT

12:00 - 13:00

Global Equity & Timely Access of Vaccines

CHAIR



Mr. Derrick Sim

Managing Director, Office of the COVAX Facility

Dr. Derrick Sim is Acting Managing Director of the Office of the COVAX Facility. In this role, he is leading the coordination of procurement and delivery of COVID-19 vaccines for 193 participating economies through COVAX, the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries.



Mr. Andrew O. Jones

Principal Advisor & Chief Vaccine Centre, UNICEF– SD

Andrew Jones currently leads a 50-member team who is responsible for procuring vaccines for low- and middle-income countries, including via COVAX. With a background in science research, he remarkably managed projects focused on vaccine delivery, emerging diseases, and other health issues in other institutions, such as Gates Foundation, CHAI - Kenya, GAVI and Canadian government in his past experience.



Ms. Tania Cernuschi

Unit Head–Agenda, Policy & Strategy (APS), Department of Immunization, Vaccines & Biologicals (IVB), Universal Health Coverage/Lifecourse Division, WHO

Tania leads WHO work on immunization agenda, policy, strategy, markets, and financing. She has twenty year experience working on political economy of health, focusing on access to health technologies and designing and managing related programmes with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training (LSE, LSHTM).



Ms. Nafisa Jiwani

Managing Director, Global Health Initiatives, U.S. International Development Finance Corporation (DFC) - America's Development bank

Ms. Jiwani provides guidance and leadership on policy and transactional matters focused on Global Health. Additionally, Nafisa is spearheading DFC's Health and Prosperity Initiative, which seeks to mobilize capital and improve resiliency in developing countries. Previously, she led health strategies as Deputy Senior Advisor to the Secretary of the Department of Health and Human Services on Value-Based Care and at the Centers for Disease Control and Prevention (CDC).



Mr. Ruchir Agarwal

Research Fellow, Harvard University

Ruchir Agarwal is an economist. He is a Research Fellow at the Harvard Kennedy School, Co-Founder of the Global Talent Lab, and currently on leave from the IMF. Until recently, he was the Head of the IMF's Global Health and Pandemic Response Taskforce and the IMF lead on the Multilateral Leaders Task Force on COVID-19 jointly established by IMF, WHO, World Bank, and WTO.



Dr. Harish Iyer

Deputy Director, Digital & Health Innovations, BMGF

Dr. Iyer is a strategic partner between Indian researchers, global partners and the Foundation teams in critical R&D work including in vaccine-preventable diseases, new approaches to treating neglected diseases, life science partnerships for public health, digital health innovations for all, reducing the digital divide. Previously, he held various R&D and leadership roles in Shantha Biotech, Biocon, Biogen-IDEC and Genentech in the US.



Ms. Zeynep Kantur Ozenci

Global Manager for Health and Education, International Finance Corporation/World Bank Group

Zeynep, who has a background in development policy, investment banking, and corporate finance, leads implementation of IFC's strategy in the health, life sciences, medtech, and education sectors. Most recently, Zeynep led development of the Global Health Platform and currently leads IFC's initiatives to establish vaccine manufacturing capacities in Africa.



Prof. Padmashree Gehl Sampath

Senior Advisor to the President Pharmaceuticals and Health, Office of the President, African Development Bank Group

Padmashree is a leading expert on technology, development and the global political economy. In parallel to her work at AfDB, she is currently a Director of the Global Access in Action Program at Harvard University; the Chair Person of the Technical Advisory Group of WHO's COVID-19 Technology Access Pool (CTAP); and a Visiting Professor who leads a project on vaccine production in Africa at the University of Johannesburg.

21
OCT

14:00 - 15:30

Regulatory & PQ

CHAIR



Dr. Mariângela Batista Galvão Simão

Assistant Director – General, Access to Medicines and Health Products, WHO

Dr. Mariângela Simão is the Assistant Director-General, Access to Medicines and Health Products; she has over 30 years of experience in the Brazilian health system. In this capacity, she actively enhanced a more equal access and decentralized management of health services in the country.



Dr. VG Somani

Drugs Controller General of India, India

Dr. VG Somani, PhD Pharmaceutical Sciences, has headed the Central Drugs Standard Control Organization (CDSCO) during 2011-12 and currently since 2019. Earlier, he served and ascended to various zonal offices by inspecting, conducting and monitoring GMP, GCP, and GLP regulations. Dr. Somani has engaged actively in national, multilateral and global forums for providing policy making, training, expertise and guidance.



Dr. Rogério Paulo Pinto de Sá Gaspar

Director-Regulation and Prequalification, WHO

Rogério Gaspar (Pharmacist, PhD), Director of the Department of Regulation and Prequalification at WHO. An academic for the last 36 years, with extensive international regulatory experience. Previously Vice-President of INFARMED, member of the MB of EMA (2000-2002), Vice-Rector of the University of Lisbon (2013-2017), member of the Executive Committee and Vice-President of the European Federation of Pharmaceutical Sciences (EUFEPS, 2009-2013; 2016-2020).



Mr. Deusdedit Mubangizi

Unit Head of the Prequalification Unit (PQT), Regulation & Prequalification Department, WHO

Mr. Mubangizi is a senior regulator with experiences in pharmaceutical products, Vaccines, Vector Control Products and In-Vitro Diagnostics, with both dossier assessment and inspection experience at national, regional and international levels. Prior to joining WHO in 2008, Mr. Mubangizi was the Chief Inspector of Drugs, where he was one of the founding staff of Uganda's national medicines regulatory agency, National Drug Authority (NDA).



Dra. Togi Junice Hutadjulu

Acting Director of Production Control Drug, Narcotic, Psychotropic and Precursor, Indonesia Food and Drug Authority, Indonesia

Ms. Togi, a Pharmacist with MSc in Health Administration, has headed Directories in Production Control Drug, Narcotics, Psychotropics, and Drug Registration at the BPOM Indonesia since 2018. In her capacity, she was invited as a member in national and regional advisory and Steering Committees for South-East Asia regional Vaccination & Immunization.



Ms. Siti Asfijah Abdoellah

Director for Drug Registration, Indonesia Food and Drug Authority, Indonesia

Ms. Asfijah, Master in Medical Science, had headed Sub Directories and Sections on clinical trial, evaluation & safety of medicines (pharmacovigilance), and medical devices registrations at the BPOM Indonesia since 1998. In her capacity, she was invited as a member of advisory, working group and assessment committees for vaccine surveillance & medicine safety by NAFDC and WHO. Currently, she leads the regulatory assistance and also the evaluation of development of a homegrown COVID-19 vaccine.

**Dr. Boitumelo Semete-Makokotlela**

CEO, South African Health Products Regulator, NRA – South Africa

She holds a Ph.D. (Biochemistry) and MSc in Management Finance and Investment, and she is a fellow at the African Leadership Initiative. Her expertise in technology innovation is notable in her scientific publications, involvement in scientific advisory committees, and leadership roles in African projects regionally and together with WHO. In the past, she served CSIR Biosciences, The Innovation Hub Management Company and McKinsey & Company. She has published as a first author and co-author in scientific publications, review articles and book chapters.

**Prof. Narendra K. Arora**

Executive Director, International Clinical Epidemiology Network (INCLEN) Trust International, India

Dr. Arora, as a paediatrician and public health expert in the immunization sector, has made major contributions at both national and global levels to the immunization sector. He has effortlessly served at the INCLEN since 2005. He is also member of the WHO's Global Advisory Committee on Vaccine Safety (GACVS); Strategic and Technical Advisory Group for Maternal, Newborn, Child and Adolescent health and nutrition (STAGE) and Member of COVAX Independent Allocation of Vaccines Group (IAVG).

**Prof. Pieter Neels**

Chair Human Vaccine Committee, IABS – Director, Vaccine Advice BV

Dr. Neels has been elected and invited for several leadership positions at the Belgian Ministry of Public Health (as senior evaluator of the clinical part or registration files), Vaccine Working Party (CHMP), International Alliance for Biological Standardization. His expertise in conducting vaccine rapporteurships has led him to establish his own company and have accepted the chair of the Human Vaccine Committee of IABS.

**Dr. Hiiti Sillo**

Unit Head, Regulation and Safety, Department of Regulation and Prequalification, WHO

Hiiti Sillo is the Unit Head, Regulation and Safety within the WHO department of Regulation and Prequalification. Until August 2021, Dr. Sillo was the Team Lead, Regulatory Systems Strengthening (RSS), Regulation and Safety Unit. Before joining WHO in January 2018, he was the Director General of the Tanzania Food and Drugs Authority (TFDA). Mr. Sillo is a Pharmacist with national, regional, and global experience in regulation of medical products.

21
OCT

16:00 - 17:40

Innovation in Finance & Technology

CHAIR



Mr. James C. Polan

Vice President of Development Credit, U.S. International Development Finance Corporation (DFC)

Prior to his current position, Mr. Polan had served as the VP for Small and Medium Enterprise Finance at the Overseas Private Investment Corporation (OPIC), before its transformation to DFC, since July 2003. In addition to his remarkable experience with investments and financial projects at OPIC, he played a key role on the agency's African and small and medium enterprise initiatives, such as the creation of OPIC's Small Business Center.



Dr. Raman Rao

CEO, Hilleman Laboratories, Singapore

Dr. Rao has over two decades experience in research and development, manufacturing and commercialization of vaccines for infectious diseases in global pharma and biotech companies. He has held several leading roles at Shantha, Sanofi and Takeda while advancing and enhancing their respective the vaccines and biologicals portfolios. Currently at Hilleman, Dr. Rao plans to carry forward Dr. Maurice Hilleman's legacy for providing effective solutions for global health especially for those impacting LMICs.



Mr. Brandon Ball

Head of Government Affairs, Temptime (a subsidiary of Zebra Technologies)

Brandon handles health policy, lobbying, and advocacy in the U.S. and internationally. That includes direct engagement with the United States (US) Congress, US Government agencies, and various global multilateral entities such as UNICEF, Gavi, the Global Fund, and COVAX. In past roles, Brandon helped lead government relations for large nonprofits, such as PATH and the UN Foundation.

**Mr. Andrew Wong**

Director of Business Development, Walvax; CEO, Shanghai Wotai Biotech

Dr. Wong holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics and human vaccine research and global registration and sales. Andrew managed three collaboration projects to support the development of bivalent, nonavalent HPV vaccines and recombinant COVID-19 vaccines.

**Dr. Kutub Mahmood**

Project Director, sIPV and NGS Projects, PATH

Expertise in viral vaccines with 30yrs experience in product development for vaccines and biologics. Over 10yrs at PATH, leading and managing projects for viral vaccines and biologics including product development strategies. Current and past projects at PATH also includes work with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and publications in peer-reviewed journals.

**Dr. Andreas Castan**

Director Strategic Technologies, Cytiva

Dr. Andreas Castan has worked for more than 20 years in the biotech industry. Prior to joining Cytiva, Dr Castan was Director Upstream Development at Swedish Orphan Biovitrum. In this current role, Dr Castan provides leadership and support to Cytiva's Bioprocess business. He is known for his profound expertise from scientific publications, book chapters, conference presentations, webinars, webcasts, interviews and articles.

**Prof. Calman A. MacLennan**

Shigella Project, BMGF

Prof. Calman MacLennan leads the Shigella and Salmonella vaccines product development portfolios at the Bill & Melinda Gates Foundation. Previously, he was Head of Exploratory Programme at the Novartis Vaccines Institute for Global Health, developing vaccines against Salmonella, Shigella and meningococcus. The Vi-CRM197 typhoid conjugate vaccines he was involved in inventing is now a licensed and WHO-prequalified vaccine manufactured by Biological E.

**Mr. Vikrant Hedau**

Technical Support Manager, Tofflon

Vikrant Hedau has been the team lead for technical support of Bio division (Tofflon India) for three years, bringing his 12+ years of experience in bioprocess industry with focus on technology transfer, and validation of vaccines and biosimilars molecules. Currently, he is heading the operational project of Single use bag manufacturing facility and the design of a successful qualification of BSL-2 manufacturing facility.

**Mr. Patrick Tippoo**

Head of Science and Innovation, Biovac – Board, DCVMN

Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and present Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and currently serves as the Vice-President of DCVMN. Mr. Tippoo is also member of the DCVMN's board.

22
OCT

09:00 – 10:00

Roadmap to Future Vaccines

CHAIR

**Dr. Birgitte K. Giersing**

Team Lead, Vaccine Prioritization & Platforms (PDR), WHO

Dr. Giersing is the Team Lead for Vaccine Prioritisation and Platforms in the Immunization, Vaccine & Biologicals (IVB) Department at WHO. She is also the secretariat for IVB's Product Development Vaccine Advisory Committee (PDVAC) and focuses on vaccine product and delivery research for priority vaccines.



Prof. Gagandeep Kang

The Wellcome Trust Research Laboratory, Christian Medical College Vellore

Professor Gagandeep Kang is internationally recognized for her observational, interventional and mechanistic research on rotavirus and enteric infections as well as the development and use of vaccines for public health programmes.



Prof. Kamel Senouci

Director, ADVAC University

Dr. Kamel Senouci is the new Director of the ADVAC Advanced Vaccinology course at the University of Geneva. During the past 20 years, he worked at the Bill & Melinda Gates Foundation, UNICEF, WHO, a global NGO and the French Ministry of Health.



Dr. Prashant Yadav

Senior Fellow, Center for Global Development

Dr. Yadav is a global expert in healthcare supply chains who serves as a Senior Fellow at the Center for Global Development, Professor at INSEAD, Lecturer at Harvard Medical School and board member in some companies & venture fund. Besides authoring several peer-reviewed scientific publications, he has had several roles in healthcare and business management academic, political, and social institutions.



Mr. Sai D. Prasad

Board Chair, DCVMN - Executive Director, Bharat

Sai Prasad is the Executive Director at Bharat Biotech. He is responsible for crucial decisions in the company with respect to operations, business development and International Collaborations. He has expertise in areas not restricted to product development, contract negotiations, technology licensing, mergers & acquisitions, fund raising, overall operations, etc.



Dr. Chunlin Xin

Vice President, CanSino Biologics

Dr. Xin, PhD in Virology, designs and develops new vaccine technologies at CanSino Biologics, where he also served as an Oncology Biomarker technical since 2017. Previously, he provided scientific and technical expertise to Novartis BioMedical Research Institute (USA and China), the National Research Institute of Canada and Merck Canada Research Institute for 15 years. Most recently, he has enabled COVID-19 tech transfer to DCVMs.

22
OCT

10:00 - 11:25

Capacity Building – Connect to Protect

CHAIR



Ms. Tania Cernuschi

Unit Head–Agenda, Policy & Strategy (APS), Department of Immunization, Vaccines & Biologicals (IVB), Universal Health Coverage/Lifecourse Division, WHO

Tania leads WHO work on immunization agenda, policy, strategy, markets, and financing. She has twenty year experience working on political economy of health, focusing on access to health technologies and designing and managing related programmes with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training (LSE, LSHTM).



Dr. Jicui Dong

Unit Head, Local Production & Assistance Unit (LPA), Regulation and Prequalification Department (RPQ), Access to Medicines and Health Products Division (MHP), WHO

Dr. Jicui DONG is the Unit Head of the WHO Local Production and Assistance Unit to support Member States in strengthening quality and sustainable local production of medicines, vaccines, diagnostics and other health products. Jicui received her MSc in Pharmacology in China, PhD in Biology in Switzerland, and MBA in the United Kingdom.

**Ms. Emma Wheatley**

Director, Access and Private Partnerships, CEPI

Having joined CEPI in 2017 and serving as Director, Access and Private Partnerships since January 2022, Emma Wheatley and her team bridge the demand for accessible, affordable medical countermeasures with the ability to build sustainable partnerships and related systems. She has over 20 years' experience on strategic transactions and collaborations in the life science industry.

**Ms. Ann Egede Ottosen**

Senior Manager, Supply Division's Vaccine Centre, UNICEF

Ann leads the Polio Unit at UNICEF Supply Division and is responsible for the procurement of vaccines in line with UNICEF's accountabilities under the Global Polio Eradication Initiative. Since she joined UNICEF she was involved in the conceptual development of the Advance Market Commitment for pneumococcal vaccines, which ensured early access for Gavi supported countries at much reduced prices. Ann joined UNICEF in 2007 from a post as director of global vaccines sales and procurement after 12 years with a public vaccine manufacturer.

**Dr. Sushant Sahastrabudhe**

Associate Director General, CARE (Clinical, Assessment, Regulatory, and Evaluation) Unit, International Vaccine Institute

Dr. Sushant (MD, MPH, MBA) has led multiple vaccine development programs involving typhoid conjugate, Chikungunya, and COVID-19 vaccines, among others, during his 12 years at IVI, South Korea. Before joining IVI, Sushant worked with National AIDS Research Institute (NARI) under the umbrella of Indian Council of Medical Research (ICMR) and International AIDS Vaccine Initiative (IAVI).

**Ms. Christina Liu**

Technical Officer, Immunization Agenda, Policy, and Strategy, WHO

Prior to joining the WHO, Christina spent 15 years in the pharmaceutical industry in a variety of commercial roles. Most recently, as the Novartis Executive Director of the Global Health Pandemic Preparedness team, she oversaw the Covid-19 Therapeutics and the Antimicrobial Resistance (AMR) programmes. Christina holds Master's degrees in business administration (MBA) and biotechnology (MB) from Wharton/University of Pennsylvania.

**Ms. Alice Ma****Senior Analyst – Market Shaping, GAVI**

Ms. Alice is responsible for leading the development of the new Healthy Markets Framework and managing the operationalization of the 2021-2025 market shaping strategy. She also manages strategic analysis and modelling for developing market strategies and external communications across the Alliance since 2015. She has research expertise on access to essential medicines and procurement strategies for health, which she developed on her various academic and non-governmental positions in China, the US and Europe.

**Ms. Julia Kuhn****Associate Program Officer, BMGF**

Julia Kuhn is an Officer on the Vaccine Development Team at the Bill & Melinda Gates Foundation. She supports CMC strategies, oversees portfolios for vaccine manufacturing workforce development and technologies to reduce animal testing among others. She received her Bachelor's degree from the University of Washington in Business Administration.

**Ms. Amanda Zehnder****Senior Organization Development and Change Management Advisor – CVIA**

Amanda Zehnder is a senior organization development and change management advisor for PATH's Center for Vaccine Innovation and Access (CVIA). She partners with teams to integrate critical people and organizational principles into their work. She previously was the Global Head of PATH's Learning, Talent, OD and HR Systems team.

**Mr. John Balchunas****Workforce Director, NIIMBL**

John Balchunas is the Workforce Director for the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) where he is responsible for guiding strategy around workforce and talent development for a federally-funded public private partnership focused on transforming biopharmaceutical manufacturing. John's career has largely centered around biopharma workforce and economic development, with past roles in leading hands-on professional development as well as regional economic and workforce development.

22
OCT

11:45 - 13:00

Key Learnings from Working Groups (by DCVMN)

CHAIR



Mr. Fernando Lobos

Business Development Director, Sinergium Biotech – Board Member, DCVMN

Mr. Lobos, an Engineer with an MBA, has over 25-years of expertise in business development, strategic planning, international business and public relations in pharmaceutical companies. Previous experience includes leadership positions in business operations, regional supply chain, and engineering in top multinational companies since 1995. He has been strongly involved in supplying vaccines for the National Immunization Program of Argentina including seasonal influenza vaccines.

CHAIR



Mr. Tiago Rocca

Strategic Partnerships & Business Development Director, Instituto Butantan - Board Member, DCVMN

Mr. Rocca has been working at Butantan for over 15 years and has assumed responsibilities in vaccines and biopharmaceuticals production, technology transfer, validation and QA. He is a pharmacist and post-graduated in Health Law at Public Health School USP and in Pharma Business Management at ESPM. Currently is the Secretary of Emerging Biopharmaceuticals Manufacturers Network (EBPMN) and member of the Board at Developing Countries Vaccine Manufacturers Network (DCVMN).



Ms. Rachel Park - Supply Chain WG

Director, Eubiologics

Rachel Park has been with EuBiologics from prequalification to commercialization of Euvichol-Plus, oral cholera vaccine since 2015. She's a director in international business at EuBiologics, responsible for marketing and collaboration with international stakeholders for its pipeline development.



Mr. Parag Nagarkar - *Regulatory Affairs WG*

Head of Global Regulatory Affairs, Serum Institute

Parag NAGARKAR is accountable for all Regulatory Affairs at Serum Institute, and member of the Indian Pharmacopeia Committee for Vaccines and Biologicals since 2012. Parag has +28 years of global pharmaceutical experience, more specifically in Regulatory Affairs, Industrial, Quality Operations and Program Management divisions that includes 25 years in Vaccine industry (with developing and developed country vaccine manufacturers).



Ms. Viska Indriani - *Pharmacovigilance WG*

Co-Chair Pharmacovigilance Working Group, DCVMN

Viska is a Medical Doctor who holds an MSC in Microbiology and Virology. She served as a consultant for Integrated Management of Childhood Illness (IMCI, USAID) and WHO, both in Timor Leste, between 2007 and 2008. Besides her experience in reproductive care and 12 years as a researcher in Bio Farma, she currently has the position as a Qualified Person for Pharmacovigilance (QPPV).



Mr. Adriansjah Azhari - *COVID Committee*

Member, DCVMN Board

Mr. Azhari has vast experience in biotechnology, Quality Management including Good Manufacturing Practices. He is a pharmacist and holds a Master's degree in Operations Management. He is currently a member of the Board of Executives of Bio Farma as Senior Executive Vice President (SEVP) overseeing Research and Development activities. He is also a member of DCVMN's board and chair of DCVMN Covid-19 committee.



Dr. Pradip Das - *3Rs / PSPT WG*

Deputy General Manager, Biological E

Dr. Pradip, M.V.Sc (Masters in Veterinary Science) Microbiology, has 16 years of experience in Quality Control related to QC testing, Batch release, Stability studies and monitoring scientist for non-clinical studies on new vaccines. Currently, he is also Chairman of DCVMN 3R WG and focus group member for scientific advice committee for WHO NC3Rs for Toxicity testing, Adventitious testing/ Potency and Immunogenicity testing.

22
OCT

14:00 - 15:30

Innovative Technologies

CHAIR



Prof. Petro Terblanche

Managing Director, Afrigen Biologics

Holding several qualifications, Prof. Petro has a successful track record in the strategic management of technology intensive organizations, playing a key part in the design and implementation of South Africa's biotechnology strategy. Acknowledged as one of the legends in science and academia, she holds the position of Managing Director of Afrigen Biologics (Pty) Ltd and also part time Professor at the North-West University.



Dr. Subhasis Banerjee

Principal Application Expert - Bioprocessing in Asia Pacific, Merck Life Sciences

Dr. Subhasis supports technical consultation for downstream processing for the APAC region. He has several peer reviewed international publications; he previously headed and supported the Manufacturing Sciences and Technology group; team of Scientists and Engineers for the region in optimizing downstream unit operations and providing scale up solutions to biological manufacturers.



Ms. Raman Rani

Manager – Bioprocess Application services, Sartorius

Ms. Raman currently leads a team of bioprocess application support at Sartorius Stedim India Pvt Limited. Having started her biopharmaceutical career in 2001 with Panacea Biotec, Ms. Raman was dedicated to the product development & manufacturing of paediatric vaccines like HibTT, Pneumococcal conjugate vaccines, Acellular pertussis, DPT based combination vaccines and also contributed for the regulatory approvals and WHO pre-qualification processes.

**Dr. Shaobin Mike Lu**

International Sales Manager, BioEngineering AG

Dr. Lu, trained in Germany, U.S., Israel and Italy, gained profound experience in the field of cell culture process monitoring and MVDA, followed by several commercial leading roles at major bioprocess vendors. Currently he is a sales and business development manager at Bioengineering AG in Switzerland, focusing in the EMEA and emerging markets.

**Mr. Devak Padmanabhan**

Quality Assurance Leader & Management Representative for Quality Systems, Biozeen

Devak Padmanabhan is a Biotechnologist by training and authorized for product release. As an expert in Regulatory qualification guidelines, 21CFR Part11, American Society of Mechanical Engineers (ASME) and Conformité Européene (CE) standards, he has qualified more than 300 equipment globally. His experience in Regulatory Affairs, Audits and Quality Assurance grew his interest in paperless validation and to become a member of the Pharma 4.0 team.

**Dr. Pratik Gajjar**

Senior Bioprocess Specialist, Univercells Technologies

Dr. Pratik is a senior bioprocess specialist dedicated to successfully implementation of scale-X technology at customer's site by assisting process development and scale up. He is also subject matter expert in Upstream and Downstream for Product Management, Marketing and Development team by contributing to provide industry trends and competitor knowledge to aid in the sales process and business objectives. He holds an Industrial PhD in Biotechnology and brings over six years of multifaceted technical expertise.

**Mr. Surajit Chandra**

Country Sales Manager – India, Nepal, Sri Lanka, Bhutan, Telstar

With 17+ years' experience in Pharma/Biotech domain joined Azbil Telstar India Ltd since Feb' 2018. Spearheading business for Integrated Process equipment, Engineering Consultancy in India, has been successful in establishing TELSTAR as a reliable partner with Tier I Pharma / Vaccine manufacturers with Company's 360 strategy.



Mr. Seshu Tirumala

National Sales Manager, Stevanato Group, India

With 25+ years of sales & technical leadership in major health organizations, Seshu gained an extensive experience in Pharma Packaging, Drug Delivery Systems, and Medical Devices. Seshu is responsible for leading integrated solutions around drug containment solutions, drug delivery and visual inspection systems, assembly & packaging, analytical and testing services in India.



Ms. Ozge Goktekin

Managing Director Europe & Asia, Pharmajet

Ms. Goktekin is the Managing Director at Pharmajet Inc., responsible from Europe & Asia. She has 25 years of commercial experience in life sciences including biotechnology and drug delivery systems



Mr. Rajkumar Gaikwad

Business Head India, Bioengineering BU, TruKing Technology Co., Ltd.

Biotechnologists, Consulting the Bioengineering Industry for more than decades, Techno commercial solution provider for stainless steel, single-use technologies, and filtration solutions for the Biopharmaceutical industry, expertise in providing end-to-end Integrated Solutions for manufacturing needs of viz. vaccines, Monoclonal antibodies (Mab), and recombinant therapeutic molecules.

22
OCT

16:00 - 17:30

CEO Forum: Horizon 2030

CHAIR



Dr. Krishna Ella

Founder, Chairman & MD, Bharat Biotech

Dr. Krishna is an entrepreneur in human & animal vaccines and food processing. He enabled Bharat Biotech to deliver over 10 billion vaccine doses to +123 developing countries. In his leadership, the company produced 17 vaccines, including the world's 1st Typhoid Conjugate and 1st COVID-19 indigenous vaccines in the world. In addition to his 6 Honorary Doctorate degrees, he has +100 awards as well as the Padma Bhushan.



Mr. Adar C. Poonawalla

CEO, Serum Institute of India

Mr. Adar has successfully led the expansion of the SII for over 170 countries, focusing on ensuring affordable, licensed and pre-qualified vaccines by WHO. New vaccines such as Rotavirus and Pneumococcal have been produced under his tenure since 2011. Even more, SII has produced 1.5 million doses of the COVID-19 vaccine and 1.5 billion of others distributed worldwide.



Ms. Mahima Datla

Managing Director, Bio E

Mahima Datla is the Managing Director of Biological E Limited, one of the leading vaccine manufacturer based in India. Over a career spanning 23 years, she has been actively engaged with several public health organisations such as GAVI, DCVMN, GHIT, Hilleman Labs, representing her organisation and the DCVMN.

**Mr. Abdul Muktadir**

Chairman and Managing Director, Incepta

Abdul Muktadir is Chairman of Incepta Pharmaceuticals and Incepta Vaccine Ltd. He is an Industrial Pharmacist by training and studied in Long Island University NY, USA. His current interest is in the area of bio-similar products and vaccines. Incepta is the second largest pharma company in Bangladesh and exports to 78 different countries.

**Prof. Mauricio Zuma Medeiros**

Director CEO, Bio FioCruz

Dr. Zuma is the elected Director at Bio-Manguinhos/Fiocruz, responsible for research, innovation, technological development and production of vaccines, diagnostic kits and biopharmaceuticals. He holds 40 years of public management and interests in strategies and technology transfer in Brazil.

**Dr. Morena Makhoana**

CEO, Biovac

Dr. Makhoana holds the role of CEO and member of the Board and Executive team in Biovac, where he has been committed to building vaccine manufacturing capacity in Southern Africa since 2010. During his tenure, Biovac secured three successful technology transfers with global pharmaceutical companies, allowing a great growth in its staff. He has a strong record of advisory positions in healthcare and non-healthcare companies.

**Dr. Ke Wu**

Founder & CEO, Bravovax

Dr./Prof. Wu Ke is the Founder and CEO of BravoBio & BravoVax. He had successfully developed 7 products being marketed in China and 20+ granted patents. He was Executive President of Shanghai Zerun Biotechnology and Director of R&D in Wuhan Institute of Biological Products, CNBG. He is Council Member of China Association for Vaccines (CAV).

**Dr. K. Anand Kumar**

Managing Director, Indian Immunologicals

Dr. Kumar is listed as a top influencer in biopharmaceutical industry with 30+ years of experience in vaccine Industry. He was publicly acknowledged for providing COVID-19 vaccines in record time. In parallel, he has established a new-Zealand company, Pristine Biologicals, for securing vaccine raw material. He is a member of the National Biotechnology Committee with CII, but already served as a member of Parenteral Drug Association (PDA) in Australia.

**Mr. Rahman Roestan**

Operations Director, PT Bio Pharma Holding

Roestan currently officiates as Operations Director of PT Bio Farma Holding. He also serves as The Experts of PP Indonesian Pharmacists Association. He began his career with Agency for the Assessment and Application of Technology Indonesia (BPPT), Organon Indonesia (Akzo Nobel). Bio Farma: President Director, Marketing Director, Corporate Secretary, Senior Manager PPIC.

**Mr. Fernando Lobos**

Business Development Director, Sinergium Biotech – Board Member, DCVMN

Mr. Lobos, an Engineer with an MBA, has over 25-years of expertise in business development, strategic planning, international business and public relations in pharmaceutical companies. Previous experience includes leadership positions in business operations, regional supply chain, and engineering in top multinational companies since 1995. He has been strongly involved in supplying vaccines for the National Immunization Program of Argentina including seasonal influenza vaccines.

**Mr. Harshet Jain**

Head for Business Development (Biologicals), Panacea Biotec

*Mr. Harshet Jain shall be representing Dr. Rajesh Jain
Harshet spends majority of his time on leading business strategy, corporate development, sales, and marketing. He is a firm believer of free markets and competition, so customers can have the best affordable experiences, and transformational power of public health for sustained economic success. With a global perspective and entrepreneurial-mind set, Harshet is an avid supporter of research and innovation.



Mr. Rajinder Suri

CEO, DCVMN

To meet un-precedented challenge posed by COVID-19, Rajinder as CEO-DCVMN is actively involved in all global strategic initiatives along with COVAX partners and industry associations to ensure equity and timely access to vaccines. He is member of several advisory expert groups including COVAX Manufacturing & Supply Task Force Leadership Team and Market Design and Demand Intelligence pillar of PAVM. He brings over 25 years of top management experience in the industry including Board of Directors of the Indian subsidiary of Sanofi Pasteur and. Rajinder has been Member- GAVI-PPC of as well as Vice-President, DCVMN Executive Committee.